12:50 EDT - Blackstone (BX) is set to make a windfall on the pending buyout of 78%-owned residential-system firm Vivint Solar(VSLR) . The company, incubated as part of BX's investment in home automation and security-services company Vivint, initially relied upon its salesforce, installation team and back office, something BX managing director Peter Wallace describes as a significant advantage in driving VSLR's fast growth. BX will take around $560M in SunEdison(SUNE) stock and convertible notes as part of the sale. SUNE, like many acquirers of late, sees its shares rise post- deal, climbing 2.4% in hitting a fresh 7-year record. SolarCity(SCTY) , the largest rival to VSLR, jumps 8.3% after sliding the past 2 months. For its part, VSLR has never closed at or above last fall's $16 IPO price.
Blackstone's Fund Raising
Blackstone has taken in $94 billion during last 12 months.
Notably, Blackstone now has undrawn capital, or "Total Dry Powder" totaling $81.1 billion, (up 80 percent Y/Y), primarily driven by funds raised by BX global private equity and real estate funds.
In addition, the two global funds were over-subscribed, according to CEO Steve Schwarzman, putting Blackstone in the position of having to turn away capital.
Blackstone Conference Call Highlights
Schwarzman pointed out, "Despite the headwinds in the public markets, we continued to deliver superior returns for our investors. In private equity, we outperformed the S&P by 370 basis points in the quarter and in real estate, we beat the REIT Index by 1250 basis points."
He continued, "In a rising rate environment, I expect our portfolio, including real estate and credit to continue to perform well, which it has historically in that type of environment; and that is because rising rates have usually come accompanied by better economic activity.
"Our credit and hedge fund platforms are scaled drivers of our financial results. Those businesses are now $150 billion of AUM or 40 to 45 percent of the firm, up from $39 billion in 2007. Those two businesses have generated over $1.4 billion in revenues over the last 12 months.
"When our investors give us a dollar, we've generated $2.00 to $2.50 on average in our private equity and real estate funds across markets and economic cycles for 30 years – this is not a one-time event."
He concluded, "With the explosive growth of the last 12 months and continuing momentum in our fundraising, we will soon have over $330 billion of money at work creating earnings which will drive significant value for unit holders to a new level reflective of that 50 percent increase in assets at work."
Cramer's 25 Investing Rules
Cramer's 10 Commandments
Cramer's Best Stocks of 2015
Mad Money Recap
Mad Money Stock Screener
Action Alerts PLUS
Charitable Trust Portfolio
Most Recent Trade Alert
25 Investing Rules
10 Trading Commandments
Cramer's Best Stocks for 2015
Stock Market Today
Gold Prices Today
Economic Events Calendar
Biotech and Drugs
Banking and Finance
Small Business News
Best Stocks for 2015
Best Funds for 2015
Best ETFs for 2015
Dividends and Income
Investing in Stocks
Investing in Bonds
Investing in Mutual Funds
Investing in ETFs
Investing in Options
Best Online Brokerage
Option Trading Strategies
Options Trading Basics
Retirement (IRAs, 401ks)
Travel - Leisure
Running a Business
Bank Safety Ratings
Insurer Safety Ratings
Individual Tax Calendar 2015
Cramer on Demand
Economics & Politics
Action Alerts PLUS
Action Alerts OPTIONS
Daily Swing Trade
Dividend Stock Advisor
Real Money Pro
Stocks Under $10
Compare All Subscription Services
Real Money Pro Portfolio
Health Care Stocks Biotech Cramer Takeaways Cramer's Mid-Year Forecast Top Dividend Stocks 10 Best ETFs Cramer's Best Stocks for 2015 Best High-Yielders
Will Blackstone (BX) Stock be Helped by This Analyst Action?
ByEiffy LuoFollow | 07/17/15 - 11:09 AM EDT
Get TheStreet Quant Ratings' exclusive 5-page report for (BX) - FREE.
NEW YORK (TheStreet) -- Blackstone Group (BX - Get Report) had its price target increased to $47 from $45 at Jefferies, which reiterated its "buy" rating.
In the current quarter, Blackstone raised $31 billion from various different investors including roughly 50% from outside the U.S., according to the analyst note.
"Despite continued elevated realization activity in recent periods, accrued performance fees as of quarter-end remained robust at $3.80 per unit, and activity levels across the businesses remain high," Jefferies analysts said.
Over the past year, Blackstone has raised $93.9 billion for an array of funds, which exceeds the total assets managed by rival Ares Management LP (ARES) and is just shy of the $99.1 billion KKR & Co. (KKR) said it managed as of March 31, The Wall Street Journal reported.
Blackstone announced its second quarter earnings results yesterday with $0.21 earnings per share on $1.2 billion revenue, down from $0.85 EPS on $2.2 billion revenue for the same period last year.
Blackstone is a global alternative asset manager and provider of financial advisory services, focusing on private equity, real estate, hedge fund solutions, secondary funds and credit business.
Shares of Blackstone Group are down 0.52% to $41.74 in mid-morning trading Friday.
Separately, TheStreet Ratings team rates BLACKSTONE GROUP LP as a Buy with a ratings score of A+. TheStreet Ratings Team has this to say about their recommendation:
"We rate BLACKSTONE GROUP LP (BX) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, solid stock price performance and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company shows weak operating cash flow.
Blackstone Meets Revised Thomson Reuters Consensus -- Market Talk
DOW JONES & COMPANY, INC. 6:39 AM ET 7/16/2015
9:39 EDT - Blackstone (BX) met Wall Street's expectations after all. Thomson Reuters revises consensus for BX 2Q economic net income per share to 43c, from 47c earlier after removing an outdated prediction from an investment bank no longer covering the firm. The tweak brings BX from a miss to meeting expectations as firm reported 43c economic net income, which accounts for unrealized gains and losses on investments as well as cash earnings. BX falls 1.6% to $40.67.
IntelliPharmaCeutics Intl (NASDAQ:IPCI) last announced its earnings results on Monday, July 13th. The company reported ($0.06) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.05) by $0.01. The company had revenue of $1.20 million for the quarter. On average, analysts predict that IntelliPharmaCeutics Intl will post $-0.1400 earnings per share for the current fiscal year.Zacks cut shares of IntelliPharmaCeutics Intl (NASDAQ:IPCI) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning,Market Beat reports.
Sentiment: Strong Buy
04:58 PM EDT, 07/15/2015 (MT Newswires) -- Kinder Morgan(KMI) reported Q2 earnings of $0.15 per share on revenue of $3.46 billion, both below the analyst consensus of $0.19 per share in earnings on $4.0 billion in revenue, according to Capital IQ.
Separately, the company disclosed an agreement with Shell (RDS.A) for Kinder Morgan(KMI) to purchase 100 percent of Shell's equity interest in Elba Liquefaction Company, LLC (ELC), the owner of the Elba Liquefaction Project, which is proposed to be constructed and operated at the existing Elba Island LNG Terminal near Savannah, Georgia. Kinder Morgan(KMI) currently owns 51 percent of the ELC joint venture. Shell owns the remaining 49 percent and subscribes to 100 percent of the liquefaction capacity.
Kinder Morgan (KMI) will purchase the remaining 49 percent of the joint venture that it does not already own. Kinder Morgan's(KMI) expected incremental investment resulting from this transaction is approximately $630 million, bringing its total incremental investment in all the liquefaction and terminal facilities at Elba Island to approximately $2.1 billion.
Blackstone’s Big Dividend Is “Money Good”
Blackstone Group shareholders should take comfort in the company's growing stockpile of accrued performance fees.
When it comes to partnerships, investors learn to love them for the distributions -- the dividend. But the distributions paid by private equity companies tend to be lumpier. After all, Blackstone Group's (NYSE:BX) routine management fees mostly keep the lights on; less-predictable performance fees are the icing on the cake that sends it into profitability.
But "lumpy" may mischaracterize Blackstone's future payouts. The company ended the latest quarter with $4.9 billion of "net accrued performance fees," equal to $4.17 per share.
Its executives like to think of its accrued performance fees as a sort of receivable; when Blackstone realizes profits earned for its fund investors, it'll pay that sum back out to its shareholders. As for timing, realizing these profits is at Blackstone's discretion, though it has to act as a fiduciary to its clients and work to maximize their profits first and foremost.
Blackstone Accrued Performance Fees
What's driving its profitability
Regardless of where an investor might think we are in the economic cycle, it's clear that valuations are up across the board. The net result is that Blackstone is accruing more and more performance fees, which will eventually be returned to shareholders as it exits investments and books gains for its clients.
On its most recent conference call, Blackstone CFO Laurence Tosi noted that $151 billion of the company's assets under management are currently earning performance fees, an increase of 30% over the prior year. One would hope and expect this to only continue growing. Tosi called this a valuable "compounding effect" that is inherent in the fee-driven business of managing other peoples' money.
When Blackstone reports earnings on Thursday, the good news should continue after a stellar first quarter kicking off 2015. Blackstone was busy fundraising for another mega fund this quarter, gathering a reported $17 billion for BCP VII, one of the largest private equity funds raised since the financial crisis. This follows a beastly $15.8 billion raised for its real estate funds in the first quarter, some of which was almost immediately deployed in a $14 billion deal for some of General Electric's real estate assets.
And although quarterly performance means little in the grand scheme of things, it's hard not to be upbeat about Blackstone's recent fundraising trends and its ability to collect fee-earning assets under management. It's rapidly replacing capital to build new funds as older funds wind down.
As merger and acquisition activity heats up in the public markets, one suspects that Blackstone's older "inventory" of smaller privately held assets might soon lead to big realizations and beefier distributions as time goes on. With $4.17 per share in the kitty in the form of accrued fees, the next few quarters could be particularly lucrative for its investors.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act quickly, you could be among the savvy investors who enjoy the profits from this stunning change. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... But you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
to be fair. Zack gave this comment..Of course it is just based on missing earning number, etc..not on prospects.. disregard them often...
Sentiment: Strong Buy
IntelliPharmaCeutics Intl (NASDAQ:IPCI) announced its quarterly results before the market opened on Monday, July 13th. The company reported ($0.06) earnings per share (EPS) for the previous quarter, missing the Thomson Reuters consensus estimate of ($0.05) EPS by $0.01. The company had revenue of $1.20 million for the quarter. (View Earnings Release) Tweet This.
IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) had its "buy" rating reaffirmed by Brean Capital ( ) (analyst Jonathan Aschoff). They now have a $8.00 price target on the stock. 124.7% upside from the previous close of $3.56. The analysts wrote, "Intellipharmaceutics reported revenue of $1.3 million and EPS of $(0.06) for its FY2Q15, versus $1.8 million and $(0.04) consensus, respectively. Total revenue during FY2Q15 came exclusively from licensing revenue from Par for commercial sales of 15 and 30mg generic Focalin XR. Over the quarter, Intellipharmaceutics faced four generic competitors for 15mg Focalin XR, which largely accounts for the revenue trajectory. We believe Par will launch the 5mg strength imminently, as the 180-day first-filer exclusivity recently ended, and this dose represented a branded value of about $73 million for Novartis in its annual 2014 sales. We believe that Par will also be able to launch 10 and 20mg Focalin XR by calendar YE15 when the 180-day exclusivity ends, further offsetting 15mg dose competition. Intellipharmaceutics need only conduct a bioequivalence trial for its proprietary Rexista Oxycodone XR versus Oxycontin, and we believe that the company has already demonstrated bioequivalence in its submission to the FDA. We believe that the company will gradually shift its focus away from ANDAs and involve itself more with proprietary products that can utilize the 505(b)(2) pathway. Intellipharmaceutics ended FY2Q15 with cash of $3 million, which should fund operations into late-2015, and there is also $10 million remaining on the company’s ATM facility.”" Tweet This.
Sentiment: Strong Buy
they own 34% or 70 million shares worth 1.9 Billion.. Bain always owns the same.. MIR came public at 18....The Michaels Companies Announces Secondary Offering of 12.5 Million Shares of Common Stock by Selling Shareholders
The Michaels Companies, Inc.
17 hours ago
IRVING, Texas, July 9, 2015 (GLOBE NEWSWIRE) -- The Michaels Companies, Inc. (MIK) (the "Company") today announced that certain of its stockholders (the "Selling Stockholders") intend to offer for sale 12.5 million shares of its common stock pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission ("SEC").
The Selling Stockholders will receive all of the net proceeds from this offering. No shares are being sold by the Company.
looks to open lower....will need the approval for the next move up I think.. patience needed as usual lwiththis stock..
as I said BX sold several positions last quarter when the market and prices were high..so I think this last quarter will be good.. will see about the future as the market and BX holdings have taken a hit...
Intellipharmaceutics Updates Status of Tentative Approvals of Generic Focalin XR(R)
Intellipharmaceutics International Inc.
1 hour ago
IntelliPharmaCeutics Internati … Watchlist
Why IntelliPharmaCeutics Just Had A Big Tuesday Benzinga 1 mth 13 days ago
IntelliPharmaCeutics International (IPCI) in Focus: Stock Jumps 5.4% - Tale of the Tape Zacks 1 mth 13 days ago
TORONTO, July 8, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today advised that the United States Food and Drug Administration ("FDA") has indicated to the Company that it has rescinded its previous requirement that the Company meet newly-imposed conditions for bioequivalence prior to receiving final approval for the Company's tentatively-approved strengths of its generic Focalin XR(R) (dexmethylphenidate hydrochloride extended-release) capsules (the "Product"). The strengths affected include 5 mg, 10 mg, 20 mg and 40 mg. The already-approved 15 mg and 30 mg strengths now in the market are not affected.
The FDA, in November 2013, had previously granted the Company tentative approvals for the 5 mg, 10 mg, 20 mg, and 40 mg strengths of its generic Focalin XR(R). Subsequently, the Company announced in a press release dated June 18, 2015, that the FDA had indicated that the Company would be required to meet newly-imposed guidelines before the affected strengths of the Product could receive final approval. The FDA has now rescinded that requirement.
The Company is not aware of any further action required of it in respect of its Abbreviated New Drug Application ("ANDA") for the Product. The Company is therefore hopeful that the FDA will shortly grant final approval for the 5 mg strength of the Product which is not subject to the six months of market exclusivity accorded to the first-filer of an ANDA. There can be no assurance that such final approval will be granted within a short time, or at all, or that further conditions will not be imposed for that strength or any of the other tentatively approved strengths.
Sentiment: Strong Buy
BX earnings out july 16th...they should be good as BX sold a lot of holdings last quarter at good prices as the market was high...took advantage of that.. but now they holdings are down as is the market so will see about next quarter..